Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Ulrich Trechsel"'
Autor:
Ian R. Reid, Jonathan R. Green, Kenneth W. Lyles, David M. Reid, Ulrich Trechsel, David J. Hosking, Dennis M. Black, Steven R. Cummings, R. Graham G. Russell, Erik F. Eriksen
Publikováno v:
Bone. 137
Zoledronate is the most potent and most long-acting bisphosphonate in clinical use, and is administered as an intravenous infusion. Its major uses are in osteoporosis, Paget's disease, and in myeloma and cancers to reduce adverse skeletal related eve
Autor:
Jean-Marc Kaufman, Jacques P. Brown, A Widmer, Philippe Jaeger, Zebulun D. Horowitz, Pierre J. Meunier, Jean-Pierre Devogelaer, Ulrich Trechsel, Jean-Jacques Body, Peter Burckhardt, Ian R. Reid, P J Richardson
Publikováno v:
Obstetrical & Gynecological Survey. 58:33-35
Although effective, oral bisphosphonate treatment for osteoporosis is limited by problems in compliance, gastrointestinal effects, and variable absorption. Intravenous bisphosphonates, given intermittently, might eliminate some problems of oral dosin
Autor:
Patrick Garnero, Jacques P. Brown, T. Fashola, Ulrich Trechsel, Stefan Goemaere, Dieter Felsenberg, Jean-Pierre Devogelaer, Peter Burckhardt, C. E. Ortmann, Jean-Jacques Body, Erik Fink Eriksen, Joel S. Krasnow, Kurt Lippuner, Liuska Sanna, Pierre J. Meunier, Göran Samsioe
Publikováno v:
Devogelaer, J P; Brown, J P; Burckhardt, P; Meunier, P J; Goemaere, S; Lippuner, K; Body, J J; Samsioe, G; Felsenberg, D; Fashola, T; Sanna, L; Ortmann, C E; Trechsel, U; Krasnow, J; Eriksen, E F; Garnero, P (2007). Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporosis international, 18(9), pp. 1211-8. London: Springer 10.1007/s00198-007-0367-3
In a 5-year study involving 119 postmenopausal women, zoledronic acid 4 mg given once-yearly for 2, 3 or 5 years was well tolerated with no evidence of excessive bone turnover reduction or any safety signals. BMD increased significantly. Bone turnove
Autor:
Michael J. Hooper, P J Richardson, Georg Leb, Göran Samsioe, Raffaele Di Micco, Philippe Jaeger, Pierre J. Meunier, Sergio Ortolani, A Widmer, Johann Broell, Jean-Jacques Body, Leon Verbruggen, Timothy M. Murray, Joachim Happ, Hans Mallmin, Jean-Marc Kaufman, Alessandro Rubinacci, Maria Sääf, Ian R. Reid, Jean-Pierre Devogelaer, Jacques P. Brown, Maria Luisa Brandi, Ulrich Trechsel, Peter Burckhardt, Zebulun D. Horowitz, Dieter Felsenberg, Andrea R. Genazzani, Jochen Ittner
Publikováno v:
The New England journal of medicine. 346(9)
Bisphosphonates are effective agents for the management of osteoporosis. Their low bioavailability and low potency necessitate frequent administration on an empty stomach, which may reduce compliance. Gastrointestinal intolerance limits maximal dosin
Autor:
Helen Thurston, Hans Runge, Ulrich Trechsel, Roland Maeumbaed, Gerhard Krehan, T. Fashola, Peter Schlüter, Ralf H Wittenberg, Klaus J Burger, Ernest Schell
Publikováno v:
Arthritis Research & Therapy. 8:R35
Cyclo-oxygenase-2 selective inhibitors are frequently used to manage osteoarthritis. We compared the analgesic efficacy of the novel cyclo-oxygenase-2 selective inhibitor lumiracoxib (Prexige®) versus placebo and celecoxib in patients with knee oste
Publikováno v:
Calcified Tissue International; May2008 Supplement, Vol. 82, p1-12, 12p, 2 Diagrams
Publikováno v:
Calcified Tissue International; May2007 Supplement, Vol. 80, p1-13, 13p
Publikováno v:
Calcified Tissue International; Jan2006 Supplement, Vol. 78, pS1-S16, 16p, 1 Color Photograph, 1 Chart
Publikováno v:
Calcified Tissue International; Jan2004 Supplement 1, Vol. 74, pS2-S139, 138p
Publikováno v:
Calcified Tissue International; Apr2003, Vol. 72 Issue 4, p279-313, 32p